- Acute Pain
- Chronic Pain
- Regional Anesthesia
- Emerging Technology
- Education
- Case Series (5 or more patients) **Patient informed consent required for submission**
- Report of up to 4 cases having a similar presentation; case series of 5 or more patients must be presented as a scientific abstract. **Patient informed consent required for submission**
- Showcase for resident quality improvement projects with a focus on chronic pain.
- IRB approval is not required for this category.
Abstract Title
Limited to 130 characters including spaces, in sentence format.
Submitting Author Details
The submitting author will receive all communications regarding the abstract and is responsible for informing the other authors, as necessary.
Co-Author(s) Details
Name, contact information, role (author, co-author, presenting author). List the primary or presenting author first. PLEASE NOTE: if the submitting author is also a co-author, they must be added to this list or they will not be recognized on the abstract or certificate of recognition.
Abstract Body
Strictly limited to 500 words over the following content areas:
- Introduction
- Material and Methods (including statement of IRB approval/waiver, IND approval, patient informed consent, etc.)
- An IRB approval statement must be included along with checking the IRB box under attestations.
- An investigator cannot determine if the IRB is needed or not. This can only be done by the IRB. If your organization's IRB policy states that, as long as there is no identifiable patient information in the case report, it is IRB exempt, this needs to be stated and documentation must be available upon request. For example, a statement could say, "As the case report is devoid of patient identifiable information, it is exempt from IRB review requirements as per (please provide name of organization) policy."
- Document any off-label indications and IND approvals, if applicable.
- Maximum 3 tables of 10 rows x 10 columns
- File type must be one of the following: .pdf, .jpg, .jpeg, .png
- Patient faces must be entirely covered.
- Maximum 2 images permitted.
- Maximum file size of each image is 30 MB.
- Maximum pixel size is 600(w) x 800(h).
- File type must be one of the following: .pdf, .jpg, .jpeg, .png
Important Considerations
- Abstracts are subject to rejection if all instructions have not been followed.
- No promotional content of a commercial entity may be included (brand/trade/product names, photos, logos, company names, etc.).
- If necessary for clarity, a trade/product name may be included parenthetically once in the Materials and Methods section, but no more, and not in the abstract title. If more than one company makes the product, all applicable trade names are identified.
- Any off-label indications should be clearly documented within the Materials and Methods section as such.
- The most common reasons for author revision requests and rejection include lack of IRB approval statements and/or missing informed consent documentation. Please double check your abstract prior to submission.
Mandatory Attestations
Conflicts of Interest Disclosure
All submissions require disclosure of financial or other relationships with ineligible companies producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Disclosure must include the company name(s) and nature of relationship (honoraria/expenses, consulting/advisory board, funded research, royalties/patent, stock options, equity position/ownership, employee, other similar relations). Disclosure is required for the submitting author over the last 24 months.
Institutional Review Board (IRB) and/or Animal Use Committee Approval (select one)
- IRB and/or animal use committee approval was either obtained or waived for the study. IMPORTANT: abstracts must include this approval/waiver statement under the Materials and Methods section.
- This is a medically challenging case and IRB approval may not be mandatory, but I will adhere to and document the process for IRB approval at my organization.
Patient Informed Consent and Protected Health Information (select all that apply)
- Patient informed consent was obtained for submission of a case report. IMPORTANT: abstracts must include this consent statement under Materials and Methods or the abstract will be rejected without review.
- All patient protected health information has been de-identified; patient faces are entirely covered.
- This is a scientific abstract with no patient protected health information.
Off-Label Drug Use (select all that apply)
- If my study involves off-label use of drugs placed near the neuraxis, I have obtained an FDA IND and/or I have followed the conditions set forth regarding such experimentation as described within How to Format Data for Presentation in the Regional Anesthesia and Pain Medicine Journal.
- If my study involves off-label use of drugs for peripheral nerve block, I have obtained IRB approval and documented IRB approval under the Materials and Methods section.
- All off-label indications have been clearly indicated as such in the abstract. IMPORTANT: abstracts without this text will be rejected.
- There are no off-label indications included.
Trade Names (select one)
- No promotional content of a commercial entity is included (brand/trade/product names, photos, logos, company names, etc.).
- If necessary for clarity, a trade/product name is included parenthetically once in the Materials and Methods section, but no more, and not in the abstract title. If more than one company makes the product, all applicable trade names are identified.
Copyrighted Material (select one)
- There are no copyrighted figures, images, or content in my abstract.
- If copyrighted figures, images, or content are contained in my abstract, I have obtained the necessary permissions from the copyright owners.
Oral Presentation
- Yes
- No
Travel Award
- Yes
- No
Agreement and Submission
- I reviewed this abstract, and all information is correct. I accept that the content of this abstract cannot be modified or corrected after final submission; I am aware that it will be published exactly as submitted.
- I and all others listed as (co-)authors contributed substantively to the writing, review, and work described by this abstract, and further affirm that it was not prepared or written by anyone not listed as an author.
- I am the sole owner and/or have the rights of all the information and content. The publication of the abstract does not infringe any third-party rights including, but not limited to, intellectual property rights. I herewith grant ASRA Pain Medicine a royalty-free, perpetual, irrevocable, nonexclusive license to use, reproduce, publish, translate, distribute, and display the abstract content.
- Submission of the abstract constitutes my consent to print and/or electronic publication (e.g. meeting website, program, other promotions, etc.).
- The submitting author is responsible for informing the other authors about the status of the abstract.
- It is the author's responsibility to maintain necessary documentation for all attestations (IRB approval/waiver, patient informed consent, copyright, etc.). ASRA Pain Medicine is not liable for any issues arising from improper documentation.
- I understand that my abstract may be immediately rejected and/or removed from any publication if it does not thoroughly comply with all of the above requirements.
Presentation During Meeting
ePoster Fee
ASRA Pain Medicine does not charge a fee to submit an abstract. However, $75 will be charged for each abstract actually accepted for ePoster presentation. This payment is non-refundable and partially offsets ASRA Pain Medicine’s cost for abstract presentation in the ePoster format. This ePoster fee is generally less expensive than printing a poster; printed posters are not accepted (except for the Best of Meeting, Resident/Fellow Travel, and Patient Safety abstracts, see Awards section below). The ePoster fee will be charged after abstract acceptance and upon online submission of the ePoster.
Meeting Pre-Registration
Registering as a meeting attendee is required. Only abstracts/ePosters by authors who register no later than the ePoster submission deadline will be included in the final program and meeting materials. Meeting registration is refundable according to the meeting cancellation policy.
Eligibility
Only authors listed on the submitted abstract may present onsite during the meeting. Investigators who have abstracts approved for presentation but fail to attend the meeting three years in a row will be prohibited from submitting abstracts for the following two years.
ePoster Display
All abstracts accepted for poster presentation during the annual meeting will be available onsite each day using ePoster technology. A plasma screen will be available in a clearly identified viewing area to browse posters electronically. In addition, authors will be assigned a designated viewing time, when they will be expected to engage and discuss their work in-person at an assigned space, for 10-15 minutes. Outside of this presentation time, the ePosters will not be formally moderated.
Moderated Poster Sessions
Upon submission, authors will have the option to indicate if they would like to be considered for oral presentation during the annual meeting. The maximum number of moderated sessions will be determined by the project management team based on program organization and meeting space; ASRA Pain Medicine will provide as many opportunities as possible. Moderated oral poster sessions will include at least one dedicated session for medically challenging cases. All other sessions will be allocated for presentation of scientific abstracts; these sessions will be structured according to category and subcategory as much as possible. The final number of presentations will be based on the quality of submitted abstracts. Posters will be moderated at various times by various moderators. Each session will be assigned 9 to 12 abstracts. Each presenter will be allocated a maximum of 8 minutes per poster (5 minutes presentation and 2-3 minutes discussion).
Awards
Eligibility
Membership in ASRA Pain Medicine is not required to submit an abstract. However, only abstracts submitted by ASRA Pain Medicine members will be considered for the Best of Meeting awards.
Best of Meeting Abstracts (Scientific Abstracts only)
The top 10 highest scoring scientific abstracts that have met all ASRA Pain Medicine abstract submission requirements and ASRA Pain Medicine membership will be sent to the Research Committee, which will select 3 Best of Meeting abstracts. Best of Meeting abstract winners benefit from the following:
- Invitation to give an oral presentation from the podium (maximum 5 minutes with 7 slides including cover and disclosure slides submitted prior to the meeting).
- Certificate of achievement (mailed by the ASRA Pain Medicine office after the meeting).
- Poster tagged in the ePoster system.
- Printed poster display in the registration area (recipients are responsible for providing a 36”x 48” printed poster; ASRA Pain Medicine will reimburse up to $100 upon receipt submission).
- Stand-up recognition at the Excellence in ASRA Pain Medicine Awards Luncheon.
- Opportunity for full abstract to be published in Regional Anesthesia & Pain Medicine (if abstract has not and will not be submitted or published elsewhere).
Best of Meeting Award recipients must participate in the above presentation activities. If a winner is unable to participate, an alternative award winner will be selected.
Resident/Fellow Travel Award
Upon submission, resident/fellow submitters have the option of having their abstract considered for the Resident/Fellow Travel award. The top 10 highest scoring resident/fellow scientific abstracts will be sent to the Research Committee chair who will then select 3 to receive an award. The Resident/Fellow Travel Award recipients benefit from the following:
- Invitation to give an oral presentation from the podium (maximum 5 minutes with 5 slides submitted prior to the meeting).
- Certificate of achievement (mailed by the ASRA Pain Medicine office after the meeting).
- Poster tagged in the ePoster system.
- Printed poster display in the registration area (recipients are responsible for providing a 36”x 48” printed poster; ASRA Pain Medicine will reimburse up to $100 upon receipt submission).
- Stand-up recognition at the Excellence in ASRA Pain Medicine Awards Luncheon.
- Opportunity for full abstract to be published in Regional Anesthesia & Pain Medicine (if abstract has not and will not be submitted or published elsewhere).
- Complimentary meeting registration (main meeting and resident/fellow program only; additional activities not included).
- Travel award covering economy airfare and two days lodging (not to exceed $1500).
Resident/Fellow Travel award recipients must be present to participate in the above presentation activities. If a winner is unable to participate, an alternative award winner will be selected.
Patient Safety Award
The Patient Safety Award was created in 2022 to recognize exemplary work in this important area. It was created in the spirit of Alice Romie, an advocate for patient safety who contributed to standardizing medication safety and educating peers about this issue. Alice passed away from breast cancer in May 2021. The Patient Safety Award recipient benefits from the following:
- Inclusion in a moderated poster session.
- Invitation to give an oral presentation from the podium (maximum 5 minutes with 5 slides submitted prior to the meeting).
- Certificate of achievement (mailed by the ASRA Pain Medicine office after the meeting).
- Poster tagged in the ePoster system.
- Printed poster display in the registration area (recipients are responsible for providing a 36”x 48” printed poster; ASRA Pain Medicine will reimburse up to $100 upon receipt submission).
- Stand-up recognition at the Excellence in ASRA Pain Medicine Awards Luncheon.
- Opportunity for full abstract to be published in Regional Anesthesia & Pain Medicine (if abstract has not and will not be submitted or published elsewhere).
Patient Safety Award recipients must be present to participate in the above presentation activities. If a winner is unable to participate, an alternative award winner will be selected.
President’s Choice
ASRA Pain Medicine President, David Provenzano, MD, continues this initiative started in 2021 to highlight additional abstracts worthy of special note. These winners benefit from the following:
- Inclusion in a moderated poster session.
- Certificate of achievement (mailed by the ASRA Pain Medicine office after the meeting).
- Poster tagged in the ePoster system.
- Invitation to give an oral presentation from the podium (maximum 5 minutes with 7 slides submitted prior to the meeting) as space is available.
Ownership/Copyright
Authors retain ownership of their content and may reproduce or adapt it for other purposes. If the content is accepted for an ASRA Pain Medicine Annual Meeting, authors grant ASRA Pain Medicine a perpetual, royalty-free license to display and publish the work in any medium, with proper credit to the authors.
Availability After Meeting
ASRA Pain Medicine Society and/or Meeting Websites
Abstracts (as submitted for initial grading) will be included on the ASRA Pain Medicine website for three years. All submitted ePosters will be available online prior to the meeting. Medically challenging cases ePosters are removed three months after the meeting and scientific abstracts after maximum three years.
Regional Anesthesia and Pain Medicine Journal (RAPM) Listing (Scientific Abstracts only)
Regional Anesthesia and Pain Medicine (RAPM) is ASRA Pain Medicine’s official journal, publishing peer-reviewed scientific and clinical studies. Scientific abstracts presented during the annual meeting are listed in the journal with abstract title, author, and affiliation data only; full abstracts are not included (with the exception of the Best of Meeting, Resident/Fellow Travel, and Patient Safety Award abstracts), but will be posted on the ASRA Pain Medicine website with a link to the RAPM journal website. Medically challenging cases will not be listed in the journal or available on the journal’s website. ePosters will not be published in the journal.
